Cusp Capital Partners Revenue and Competitors
Estimated Revenue & Valuation
- Cusp Capital Partners's estimated annual revenue is currently $3.2M per year.
- Cusp Capital Partners's estimated revenue per employee is $104,000
Employee Data
- Cusp Capital Partners has 31 Employees.
- Cusp Capital Partners grew their employee count by 15% last year.
Cusp Capital Partners's People
| Name | Title | Email/Phone |
|---|
Cusp Capital Partners Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $1.7M | 26 | -4% | $15.7M | N/A |
#2 | $1.4M | 21 | -50% | $21.2M | N/A |
#3 | $41.9M | 293 | 8% | $6M | N/A |
#4 | $6M | 53 | -22% | $216.8M | N/A |
#5 | $0M | 2 | 0% | $33.3M | N/A |
#6 | $26M | 182 | 0% | N/A | N/A |
#7 | $30.9M | 221 | -26% | $64.6M | N/A |
#8 | $28.6M | 205 | -22% | $46.8M | N/A |
#9 | $249.1M | 1340 | 15% | $75M | N/A |
#10 | $12.4M | 95 | 3% | N/A | N/A |
What Is Cusp Capital Partners?
N/A
Total Funding
31
Number of Employees
$3.2M
Revenue (est)
15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Cusp Capital Partners News
2022-04-17 - Biotech venture capital: Top 10 money-raisers of 2021
Investors: GV (formerly Google Ventures), Arch Venture Partners, ... in genomics and neurobiology have brought neuroscience R&D to the cusp of a new era,...
2022-04-17 - AbbVie shreds alpha-synuclein Parkinson's pact on cusp of ...
BioArctic, the Swedish biotech that out-licensed ABBV-0805 to AbbVie, expected its partner to join the ranks of drug developers with alpha-...
2022-03-30 - VideaHealth raises $20M for AI-enabled dental care
"We are on the cusp of revolutionizing the dental industry, which is evidenced by the caliber of investment partners like Spark Capital and...
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $3.7M | 31 | 7% | N/A |
#2 | $3.6M | 31 | -14% | N/A |
#3 | $4.5M | 31 | -14% | N/A |
#4 | $6.7M | 31 | -11% | N/A |
#5 | $6.7M | 31 | 3% | N/A |